23 de octubre de 2019
  • Martes, 22 de Octubre
  • 7 de septiembre de 2009

    Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for Longer


    - The number of missed workdays in the group receiving combination
    treatment of Enbrel and methotrexate (14.2 days) was approximately half
    that of patients receiving methotrexate monotherapy (31.9 days)
    - In total, the Enbrel combination group missed up to 37 fewer total days
    due to absenteeism than the methotrexate monotherapy group
    - 24 per cent of patients in the monotherapy group had to stop work at
    least once during the year, compared to 8.6 per cent of patients in the
    combination therapy group

    Previously published data from the COMET trial showed that early treatment of RA can halt the joint damage seen as the disease progresses - 80 per cent of patients in the combination group experienced no further joint damage as measured by x-rays. Furthermore, 50 per cent of patients experienced a sustained reduction in disease activity as measured by the number of swollen joints (i.e. clinical remission) and 55 per cent achieved normal physical functioning, as measured by the Health Assessment Questionnaire.[3]

    To access further media information relating to this press release, additional information on ENBREL and future media announcements, please register on the media centre at http://www.wyeth.eu.

    References

    1. Anis A et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology doi:10.1093/rheumatology/kep239. E-Pub, 18 August 2009

    2. Lundkvist et al. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8 (Suppl.2):S49-60

    3. Emery P et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-382

    For further information, please contact: Wyeth: Gill Markham, Communications - Europe, Middle East and Africa, Direct Tel: +44-(0)1628-692536, Mob: +44-(0)-777-082-7753, Email: markhagl@wyeth.com. OgilvyHealthPR: Mary Barrington-Ward, Tel: +44-207-108-6066, Email: mary.barrington-ward@ohpr.com